BDSI up +2.90% percent Today $BDSI High is at 15.08 and the Low 14.47 with current volume of 161,322.
Recent News posted below.
Biodelivery Sciences International BDSI other info.
http://investorshangout.com/Biodelivery-Scien...DSI-53473/
BDSI Biodelivery Sciences International Recent Headline News
BioDelivery Sciences International (BDSI) Marked As A Dead Cat Bounce Stock
at The Street - Mon Nov 17, 9:05AM CST
Trade-Ideas LLC identified BioDelivery Sciences International (BDSI) as a "dead cat bounce" (down big yesterday but up big today) candidate
BDSI: 14.59 (+0.12)
BioDelivery Sciences to Present at the Stifel 2014 Healthcare Conference and the Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu Nov 13, 6:00AM CST
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at two upcoming investor conferences:
BDSI: 14.59 (+0.12)
BioDelivery Sciences' (BDSI) CEO Mark Sirgo Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 4:21PM CST
BDSI: 14.59 (+0.12)
BioDelivery Sciences to Present at the Credit Suisse 2014 Healthcare Conference
PR Newswire - Fri Nov 07, 9:34AM CST
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Credit Suisse 2014 Healthcare Conference. The presentation is scheduled for Wednesday, November 12, 2014 at 11:30 a.m. MST (1:30 p.m. EST) at the Arizona Biltmore in Phoenix, Arizona.
BDSI: 14.59 (+0.12)
Why Earnings Season Could Be Great for BioDelivery Sciences (BDSI) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:45AM CST
Investors are always looking for stocks that are poised to beat at earnings season and BioDelivery Sciences International, Inc. (BDSI) may be one such company.
BDSI: 14.59 (+0.12)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 14.59 (+0.12), PFE: 30.35 (+0.01), AMGN: 159.29 (+1.61), AXN: 0.23 (unch), SRNE: 4.18 (-0.05), NKTR: 13.83 (+0.20), EGLT: 6.12 (-0.21), AZN: 72.51 (-0.34), VBAY: ()
BioDelivery Sciences misses by $0.27, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 5:30PM CST
BDSI: 14.59 (+0.12)
Will Isis Pharmaceuticals (ISIS) Disappoint on Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 5:00PM CST
Isis Pharmaceuticals (ISIS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 7.
MNK: 88.35 (+0.24), BDSI: 14.59 (+0.12), ISIS: 49.00 (-0.01), GSK: 45.92 (+0.18)
U.S. launch of Bunavail commences
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 9:20AM CST
BDSI: 14.59 (+0.12)
BioDelivery Sciences Announces the Availability of BUNAVAIL(TM) in the U.S.
PR Newswire - Mon Nov 03, 6:00AM CST
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) is now commercially available. FDA-approved for the maintenance treatment of opioid dependence and to be used as part of a complete treatment plan to include counseling and psychosocial support, BUNAVAIL has been shipped to wholesalers and is anticipated to be available by prescription at retail pharmacies across the U.S. by the end of this week, thus commencing the full U.S. launch.
BDSI: 14.59 (+0.12)
BioDelivery Sciences to Develop a Long-Acting Injectable Depot Formulation of Buprenorphine with Evonik for Use in Opioid Dependence and Pain
PR Newswire - Tue Oct 28, 7:00AM CDT
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) has entered into an exclusive agreement with Evonik Corporation to develop and commercialize a proprietary, injectable microparticle formulation of buprenorphine potentially capable of providing 30 days of continuous therapy following a single subcutaneous injection.
BDSI: 14.59 (+0.12)
Surprising Stocks That Performed Best for Billionaires in 2014
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the best for 19 billionaires who made their money investing.
BDSI: 14.59 (+0.12), ATHL: 58.40 (unch), VIPS: 23.61 (-0.86), ARII: 66.87 (+0.08), SBAC: 112.85 (-0.19), BIOF: 7.28 (+0.01), BKW: 32.22 (-0.07), LUV: 39.34 (+0.39), HCA: 65.33 (+2.39), LPDX: 5.23 (-0.01), DTV: 87.00 (-0.55), RCPT: 103.37 (-3.18), WMB: 54.22 (+0.17), BRK.B: 145.10 (-0.42), BRK.A: 217,720.00 (-303.00), SBGL: 7.08 (+0.03), AN: 57.45 (+0.07)
Cramer's Lightning Round - Southern Company Grows Its Dividend Over Time (10/24/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Oct 26, 5:22AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday October 24. Bullish Calls: Southern Company (NYSE: SO ): "I like this. I like a company that grows the dividend over time." BioDelivery...
BDSI: 14.59 (+0.12), NLNK: 31.39 (+0.85), PAA: 52.77 (-0.23), SO: 47.04 (+0.40), HLSS: 19.06 (+0.14)
'Mad Money' Lightning Round: You're in Great Shape With Southern
at The Street - Sat Oct 25, 5:00AM CDT
Cramer says NewLink Genetics is too expensive, Home Loan Servicing is too risky but Plains All American Pipeline is terrific.
BDSI: 14.59 (+0.12), SO: 47.04 (+0.40), PAA: 52.77 (-0.23), HLSS: 19.06 (+0.14)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Oct 24, 6:54PM CDT
Earnings will take center stage and Cramer will be watching Merck, Twitter and Facebook, among many others.
BDSI: 14.59 (+0.12), GPRO: 82.26 (+3.11), MCK: 204.80 (-0.45), AXP: 89.95 (-0.72), PNRA: 169.58 (-0.18), FB: 74.14 (-0.74), DECK: 93.04 (+1.25), XOM: 94.89 (-0.20), BWLD: 160.40 (-2.27), SO: 47.04 (+0.40), PANW: 109.86 (-0.92), PAA: 52.77 (-0.23), WLP: 127.55 (+2.19), SBUX: 77.95 (-0.17), PH: 128.90 (+0.46), GILD: 100.44 (-1.62), MRK: 59.67 (+0.60), DD: 70.49 (-0.31), PAY: 36.62 (+0.17), TWTR: 40.84 (-1.01), CVX: 115.87 (-0.45), AAPL: 114.09 (-0.09), HLSS: 19.06 (+0.14)
BioDelivery Sciences elects J Chris Prue as VP of Regulatory Affairs and Quality Assurance
M2 - Mon Oct 13, 5:53AM CDT
Pharmaceutical company BioDelivery Sciences International (NasdaqCM:BDSI) disclosed on Friday the election of J Chris Prue, RPh, MBA as vice president of its Regulatory Affairs and Quality Assurance.
BDSI: 14.59 (+0.12)
BioDelivery Sciences Announces the Hiring of J. Chris Prue as Vice President of Regulatory Affairs and Quality Assurance
PR Newswire - Fri Oct 10, 10:15AM CDT
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that J. Chris Prue, RPh, MBA has joined BDSI as Vice President of Regulatory Affairs and Quality Assurance.
BDSI: 14.59 (+0.12)
Shares of BDSI Up 93.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Oct 10, 9:23AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on April 24th, 2014 at $8.61. In approximately 6 months, BioDelivery Sciences has returned 93.03% as of today's recent price of $16.61.
BDSI: 14.59 (+0.12)
Downgrade Alert for BioDelivery Sciences (BDSI)
Comtex SmarTrend(R) - Fri Oct 10, 6:57AM CDT
BioDelivery Sciences (NASDAQ:BDSI) was downgraded from Buy to Neutral at Roth Capital today. The stock closed yesterday at $17.03 on volume of 1.1 million shares, below average daily volume of 1.5 million. BioDelivery Sciences share prices have moved between a 52-week high of $18.48 and a 52-week low of $4.16 and closed yesterday at 309% above that low price at $17.03 per share. Over the last five market days, the 200-day moving average (MA) has gone up 1.7% while the 50-day MA has advanced 1.8%.
BDSI: 14.59 (+0.12)
BioDelivery Sciences Surpasses +200% YTD Gain
at The Street - Tue Oct 07, 12:23PM CDT
21Vianet Group (NASDAQ:VNET), Petroleo Brasileiro Petrobras SA (NYSE
BR) and BioDelivery Sciences International Inc. (NASDAQ:BDSI) got a strong start to the day this Tuesday. In the red midday are En...
VNET: 20.83 (-0.56), BDSI: 14.59 (+0.12), PBR: 9.37 (-0.58), DLIA: 0.10 (-0.01), END: 0.16 (-0.03)
Recent News posted below.
Biodelivery Sciences International BDSI other info.
http://investorshangout.com/Biodelivery-Scien...DSI-53473/
BDSI Biodelivery Sciences International Recent Headline News
BioDelivery Sciences International (BDSI) Marked As A Dead Cat Bounce Stock
at The Street - Mon Nov 17, 9:05AM CST
Trade-Ideas LLC identified BioDelivery Sciences International (BDSI) as a "dead cat bounce" (down big yesterday but up big today) candidate
BDSI: 14.59 (+0.12)
BioDelivery Sciences to Present at the Stifel 2014 Healthcare Conference and the Jefferies 2014 Global Healthcare Conference
PR Newswire - Thu Nov 13, 6:00AM CST
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at two upcoming investor conferences:
BDSI: 14.59 (+0.12)
BioDelivery Sciences' (BDSI) CEO Mark Sirgo Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 4:21PM CST
BDSI: 14.59 (+0.12)
BioDelivery Sciences to Present at the Credit Suisse 2014 Healthcare Conference
PR Newswire - Fri Nov 07, 9:34AM CST
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Credit Suisse 2014 Healthcare Conference. The presentation is scheduled for Wednesday, November 12, 2014 at 11:30 a.m. MST (1:30 p.m. EST) at the Arizona Biltmore in Phoenix, Arizona.
BDSI: 14.59 (+0.12)
Why Earnings Season Could Be Great for BioDelivery Sciences (BDSI) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:45AM CST
Investors are always looking for stocks that are poised to beat at earnings season and BioDelivery Sciences International, Inc. (BDSI) may be one such company.
BDSI: 14.59 (+0.12)
Cancer Pain Therapeutics Pipeline Report 2014 - 30 Companies & 43 Drug Profiles
M2 - Thu Nov 06, 4:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/9s5fww/cancer_pain) has announced the addition of the "Cancer Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Amgen Inc. - AstraZeneca PLC - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Daiichi Sankyo Company, Limited - Egalet Corporation - Aphios Corporation - Nippon Kayaku Co., Ltd. - Nippon Shinyaku Co., Ltd. - Orion Oyj - Pfizer Inc. - Zeria Pharmaceutical Co Ltd - GW Pharmaceuticals plc - IntelGenx Corp. - Benitec Biopharma Limited - Kolon Life Science, Inc. - Teikoku Seiyaku Co., Ltd. - Aoxing Pharmaceutical Company, Inc - BCN Peptides, S.A. - Grunenthal GmbH - AngioChem Inc. - WEX Pharmaceuticals Inc. - Virobay Inc. - Dimerix Bioscience Pty Ltd - Winston Pharmaceuticals, Inc. - Encore Therapeutics Inc. - Sorrento Therapeutics, Inc. - Afferent Pharmaceuticals, Inc. - ChironWells GmbH - Northern Light Pharmaceuticals AB For more information visit http://www.researchandmarkets.com/research/9s...ancer_pain
BDSI: 14.59 (+0.12), PFE: 30.35 (+0.01), AMGN: 159.29 (+1.61), AXN: 0.23 (unch), SRNE: 4.18 (-0.05), NKTR: 13.83 (+0.20), EGLT: 6.12 (-0.21), AZN: 72.51 (-0.34), VBAY: ()
BioDelivery Sciences misses by $0.27, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 5:30PM CST
BDSI: 14.59 (+0.12)
Will Isis Pharmaceuticals (ISIS) Disappoint on Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 5:00PM CST
Isis Pharmaceuticals (ISIS) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 7.
MNK: 88.35 (+0.24), BDSI: 14.59 (+0.12), ISIS: 49.00 (-0.01), GSK: 45.92 (+0.18)
U.S. launch of Bunavail commences
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 9:20AM CST
BDSI: 14.59 (+0.12)
BioDelivery Sciences Announces the Availability of BUNAVAIL(TM) in the U.S.
PR Newswire - Mon Nov 03, 6:00AM CST
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that BUNAVAIL(TM) (buprenorphine and naloxone) buccal film (CIII) is now commercially available. FDA-approved for the maintenance treatment of opioid dependence and to be used as part of a complete treatment plan to include counseling and psychosocial support, BUNAVAIL has been shipped to wholesalers and is anticipated to be available by prescription at retail pharmacies across the U.S. by the end of this week, thus commencing the full U.S. launch.
BDSI: 14.59 (+0.12)
BioDelivery Sciences to Develop a Long-Acting Injectable Depot Formulation of Buprenorphine with Evonik for Use in Opioid Dependence and Pain
PR Newswire - Tue Oct 28, 7:00AM CDT
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) has entered into an exclusive agreement with Evonik Corporation to develop and commercialize a proprietary, injectable microparticle formulation of buprenorphine potentially capable of providing 30 days of continuous therapy following a single subcutaneous injection.
BDSI: 14.59 (+0.12)
Surprising Stocks That Performed Best for Billionaires in 2014
at The Street - Mon Oct 27, 7:48AM CDT
See the stocks that have performed the best for 19 billionaires who made their money investing.
BDSI: 14.59 (+0.12), ATHL: 58.40 (unch), VIPS: 23.61 (-0.86), ARII: 66.87 (+0.08), SBAC: 112.85 (-0.19), BIOF: 7.28 (+0.01), BKW: 32.22 (-0.07), LUV: 39.34 (+0.39), HCA: 65.33 (+2.39), LPDX: 5.23 (-0.01), DTV: 87.00 (-0.55), RCPT: 103.37 (-3.18), WMB: 54.22 (+0.17), BRK.B: 145.10 (-0.42), BRK.A: 217,720.00 (-303.00), SBGL: 7.08 (+0.03), AN: 57.45 (+0.07)
Cramer's Lightning Round - Southern Company Grows Its Dividend Over Time (10/24/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Oct 26, 5:22AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday October 24. Bullish Calls: Southern Company (NYSE: SO ): "I like this. I like a company that grows the dividend over time." BioDelivery...
BDSI: 14.59 (+0.12), NLNK: 31.39 (+0.85), PAA: 52.77 (-0.23), SO: 47.04 (+0.40), HLSS: 19.06 (+0.14)
'Mad Money' Lightning Round: You're in Great Shape With Southern
at The Street - Sat Oct 25, 5:00AM CDT
Cramer says NewLink Genetics is too expensive, Home Loan Servicing is too risky but Plains All American Pipeline is terrific.
BDSI: 14.59 (+0.12), SO: 47.04 (+0.40), PAA: 52.77 (-0.23), HLSS: 19.06 (+0.14)
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan
at The Street - Fri Oct 24, 6:54PM CDT
Earnings will take center stage and Cramer will be watching Merck, Twitter and Facebook, among many others.
BDSI: 14.59 (+0.12), GPRO: 82.26 (+3.11), MCK: 204.80 (-0.45), AXP: 89.95 (-0.72), PNRA: 169.58 (-0.18), FB: 74.14 (-0.74), DECK: 93.04 (+1.25), XOM: 94.89 (-0.20), BWLD: 160.40 (-2.27), SO: 47.04 (+0.40), PANW: 109.86 (-0.92), PAA: 52.77 (-0.23), WLP: 127.55 (+2.19), SBUX: 77.95 (-0.17), PH: 128.90 (+0.46), GILD: 100.44 (-1.62), MRK: 59.67 (+0.60), DD: 70.49 (-0.31), PAY: 36.62 (+0.17), TWTR: 40.84 (-1.01), CVX: 115.87 (-0.45), AAPL: 114.09 (-0.09), HLSS: 19.06 (+0.14)
BioDelivery Sciences elects J Chris Prue as VP of Regulatory Affairs and Quality Assurance
M2 - Mon Oct 13, 5:53AM CDT
Pharmaceutical company BioDelivery Sciences International (NasdaqCM:BDSI) disclosed on Friday the election of J Chris Prue, RPh, MBA as vice president of its Regulatory Affairs and Quality Assurance.
BDSI: 14.59 (+0.12)
BioDelivery Sciences Announces the Hiring of J. Chris Prue as Vice President of Regulatory Affairs and Quality Assurance
PR Newswire - Fri Oct 10, 10:15AM CDT
BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that J. Chris Prue, RPh, MBA has joined BDSI as Vice President of Regulatory Affairs and Quality Assurance.
BDSI: 14.59 (+0.12)
Shares of BDSI Up 93.0% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Oct 10, 9:23AM CDT
SmarTrend identified an Uptrend for BioDelivery Sciences (NASDAQ:BDSI) on April 24th, 2014 at $8.61. In approximately 6 months, BioDelivery Sciences has returned 93.03% as of today's recent price of $16.61.
BDSI: 14.59 (+0.12)
Downgrade Alert for BioDelivery Sciences (BDSI)
Comtex SmarTrend(R) - Fri Oct 10, 6:57AM CDT
BioDelivery Sciences (NASDAQ:BDSI) was downgraded from Buy to Neutral at Roth Capital today. The stock closed yesterday at $17.03 on volume of 1.1 million shares, below average daily volume of 1.5 million. BioDelivery Sciences share prices have moved between a 52-week high of $18.48 and a 52-week low of $4.16 and closed yesterday at 309% above that low price at $17.03 per share. Over the last five market days, the 200-day moving average (MA) has gone up 1.7% while the 50-day MA has advanced 1.8%.
BDSI: 14.59 (+0.12)
BioDelivery Sciences Surpasses +200% YTD Gain
at The Street - Tue Oct 07, 12:23PM CDT
21Vianet Group (NASDAQ:VNET), Petroleo Brasileiro Petrobras SA (NYSE
BR) and BioDelivery Sciences International Inc. (NASDAQ:BDSI) got a strong start to the day this Tuesday. In the red midday are En... VNET: 20.83 (-0.56), BDSI: 14.59 (+0.12), PBR: 9.37 (-0.58), DLIA: 0.10 (-0.01), END: 0.16 (-0.03)
